[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338243-105":59,"doc-detail-338243-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","comparison-of-clinicopathological-characteristics-efficacy-of-neoadjuvant-therapy-and-prognosis-in-her2-low-and-her2-ultralow-breast-cancer","Comparison of clinicopathological characteristics, efficacy of neoadjuvant therapy, and prognosis in HER2-low and HER2-ultralow breast cancer","","Background: This study evaluates clinicopathological differences, neoadjuvant therapy (NAT) efficacy, and clinical outcomes among HER2-null, HER2-ultralow, and HER2-low breast cancers. Methods: Consecutive NAT-treated HER2-negative cases were classified by HER2 staining and definition, followed by subgroup analysis by HER2 expression level. Results: Among 302 patients, HER2-low predominated (71.19%), with HER2-ultralow and HER2-null at 19.54% and 9.27%. HER2-low showed higher ER/PR/AR and luminal prevalence versus HER2-ultralow, while lymph node metastasis differed between HER2-ultralow and HER2-null. Pathologic complete response varied across groups, but disease-free survival was comparable; RCB-0/I in HER2-low correlated with better DFS. Discordance in immunohistochemistry scores was frequent and often driven by HER2-0 to HER2-low conversion after NAT. Conclusions: HER2-low and HER2-ultralow tumors exhibit distinct clinicopathological features and RCB predicts prognosis in HER2-low populations.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comparison-of-clinicopathological-characteristics-efficacy-of-neoadjuvant-therapy-and-prognosis-in-her2-low-and-her2-ultralow-breast-cancer/338243/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comparison-of-clinicopathological-characteristics-efficacy-of-neoadjuvant-therapy-and-prognosis-in-her2-low-and-her2-ultralow-breast-cancer/338243.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",23,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How were patients classified into HER2-null, HER2-ultralow, and HER2-low groups?","Question",{"text":113,"@type":114},"Patients with HER2-negative breast cancer receiving NAT were classified by HER2 staining patterns and in situ hybridisation results: HER2-null had no staining, HER2-ultralow had incomplete faint staining in ≤10% of tumor cells, and HER2-low included HER2-1+ or HER2-2+ with FISH-negative status.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What differences in clinicopathology were reported between HER2-low and HER2-ultralow groups?",{"text":118,"@type":114},"Compared with the HER2-ultralow group, HER2-low tumors showed higher expression frequencies of ER, PR, and AR, and a greater prevalence of the luminal subtype.",{"name":120,"@type":111,"acceptedAnswer":121},"How did RCB relate to disease-free survival in HER2-low patients?",{"text":122,"@type":114},"Among HER2-low patients, better treatment response (RCB-0/I) was associated with significantly better disease-free survival than significant residual disease (RCB-II/III).","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},338243,1790185198,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Guan et al. Diagnostic Pathology (2024) 19:131 [https://doi.org/10.1186/s13000-024-01557-3](https://doi.org/10.1186/s13000-024-01557-3)  \nDiagnostic Pathology  \nRESEARCH Open Access  \nComparison of clinicopathological characteristics, efficacy of neoadjuvant therapy, and prognosis in HER2-low and HER2-ultralow breast cancer  \nFeng Guan 1†, Xianli Ju 1†, Lixia Chen2,3, Jiacai Ren 1, Xiaokang Ke 1, Bin Luo 1, Aol ing Huang 1 and Jingping Yuan 1*  \nAbstract  \nBackground This study aims to analyze potential differences in clinicopathology, efficacy of neoadjuvant therapy (NAT), and clinical outcome among HER2-null, HER2-ultralow and HER2-low breast cancers.  \nMethods Consecutive cases of HER2-negative breast cancer that received NAT were included. They were classified as HER2-null (no staining), HER2-ultralow (incomplete faint staining in ≤ 10% of tumour cells) and HER2-low (HER2-1 + or HER2-2+, in situ hybridisation negative) . Subgroup analysis was performed based on the HER2 expression level. Results Out of 302 patients, 215 (71 . 19%) were HER2-low, 59 (19 . 54%) were HER2-ultralow, and 28 (9 . 27%) were HER2-null. In comparison to the HER2-ultralow group, the HER2-low group exhibited higher expression frequencies of ER (p \u003C 0. 001), PR (p \u003C 0. 001), and AR (p = 0 . 004), along with a greater prevalence of the luminal subtype (p \u003C 0. 001) . The HER2-ultralow group also demonstrated a higher prevalence of lymph node metastasis compared to the HER2-null group (p = 0 . 026) . Varied rates of pathologic complete response (pCR) were observed among the three subgroups: HER2-null, HER2-ultralow, and HER2-low, with rates of 35 . 71%, 22 . 03%, and 12. 56%, respectively. Only the HER2-low subgroup exhibited a significant difference compared to HER2-null (p = 0 . 001) . Despite variations in pCR rates, the three subgroups exhibited comparable disease-free survival (DFS) (p = 0 . 571) . Importantly, we found HER2-low patients with better treatment response (RCB-0/I) exhibited significantly better DFS than those with significant residual disease (RCB-II/III) (P = 0 . 036) . The overall rate of HER2 immunohistochemical score discordance was 45 . 24%, mostly driven by the conversion between HER2-0 and HER2-low phenotype. Notably, 32 . 19% of cases initially classified as HER2-0 phenotype on baseline biopsy were later reclassified as HER2-low after neoadjuvant therapy, and it is noteworthy that 22 out of these cases (78 . 57%) originally had an HER2-ultralow status in the pretreatment biopsy sample.  \nConclusions Our results demonstrate the distinct clinicopathological features of HER2-low and HER2-ultralow breast tumors and confirm that RCB is an effective predictor of prognosis in HER2-low populations for the first time. Notably,  \n†Feng Guan and Xianli Ju contributed equally to this work.  \n*Correspondence: Jingping Yuan [yuanjingping@whu.edu.cn](yuanjingping@whu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://](http://)[","cbCailBLM4kqKMYf","https://ap.wps.com/l/cbCailBLM4kqKMYf","pdf",4128165,14,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusions\n# Keywords\n# Introduction","[{\"question\":\"How were patients classified into HER2-null, HER2-ultralow, and HER2-low groups?\",\"answer\":\"Patients with HER2-negative breast cancer receiving NAT were classified by HER2 staining patterns and in situ hybridisation results: HER2-null had no staining, HER2-ultralow had incomplete faint staining in ≤10% of tumor cells, and HER2-low included HER2-1+ or HER2-2+ with FISH-negative status.\"},{\"question\":\"What differences in clinicopathology were reported between HER2-low and HER2-ultralow groups?\",\"answer\":\"Compared with the HER2-ultralow group, HER2-low tumors showed higher expression frequencies of ER, PR, and AR, and a greater prevalence of the luminal subtype.\"},{\"question\":\"How did RCB relate to disease-free survival in HER2-low patients?\",\"answer\":\"Among HER2-low patients, better treatment response (RCB-0/I) was associated with significantly better disease-free survival than significant residual disease (RCB-II/III).\"}]","Comparison of clinicopathological characteristics, efficacy of neoadjuvant therapy, and prognosis in HER2-low and HER2-ultralow breast cancer | PDF",1790022706,35,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6a5fb4cf9d3edd448fe988e7975d6e5.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/15e3993723e86254e040a15bafd061ff.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2711ad4e6428932375ca36d18ec4e3e3.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f07a3e802d90cc8b07aa517fe583f35.webp",980,1306]